Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 13/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9194817 | 0.91 | CYP17A1 (0.50) | CYP17A1CYP19A1ADRB2TSHR | |
| SCHEMBL9192600 | 0.86 | CYP17A1 (0.52) | CYP17A1CYP19A1ADRB2TSHRCYP24A1 | |
| SCHEMBL9190479 | 0.84 | CYP17A1 (0.47) | CYP17A1CYP19A1CYP24A1 | |
| SCHEMBL9663438 | 0.83 | CYP17A1 (0.61) | CYP17A1CYP19A1 | |
| SCHEMBL9727815 | 0.81 | CYP17A1 (0.47) | CYP17A1CYP19A1CYP24A1 | |
| SCHEMBL9190551 | 0.80 | CYP19A1 (0.50) | CYP17A1CYP19A1ADRB2TSHR | |
| SCHEMBL27269281 | 0.79 | CYP17A1 (0.50) | CYP17A1CYP19A1 | |
| SCHEMBL9191682 | 0.77 | CYP19A1 (0.62) | CYP17A1CYP19A1 | |
| SCHEMBL12049974 | 0.76 | CYP19A1 (0.50) | CYP17A1CYP19A1CYP24A1 | |
| SCHEMBL10477336 | 0.76 | CYP19A1 (0.61) | CYP17A1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0371564-B1 | (1H-azol-1-ylmethyl)substituted quinoline, quinazoline or quinoxaline derivatives | JANSSEN PHARMACEUTICA NV (BE) | 1995-07-12 | — | — | EP | disclosed |
| US-5151421-A | Compounds for inhibition of metabolism of retinoids, for treatment for proliferation of epithelial cells and keratin disorders | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-09-29 | — | — | US | disclosed |
| US-5028606-A | Retinoid metabolism inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-07-02 | — | — | US | disclosed |
| EP-0371564-A2 | (1H-azol-1-ylmethyl)substituted quinoline, quinazoline or quinoxaline derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1990-06-06 | — | — | EP | disclosed |